Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma
pubmed link
full article download
"DLL3 immunostaining was intense and homogeneous in IDH mutant gliomas, retained in all recurrent tumors, and detected in only 1 of 20 non-tumor brains. Patient-derived IDH mutant glioma tumorspheres overexpressed DLL3 and were potently sensitive to Rova-T in an antigen-dependent manner."
This is particularly interesting because the therapy is currently available in a clinical trial for recurrent GBM and other solid tumors recruiting at multiple locations across the USA.
https://clinicaltrials.gov/ct2/show/study/NCT02709889?show_locs=Y#locn
No comments:
Post a Comment